Skip to main content

Table 1 Changes from baseline to end of Week 12 in secondary endpoints in patients with PAH-CHD in PATENT-1 (observed values):

From: Riociguat for pulmonary arterial hypertension (PAH) associated with congenital heart disease (CHD): A subgroup analysis from the PATENT studies

  Placebo Riociguat 2.5 mg–maximum Riociguat 1.5 mg–maximum
  n Baseline Change from baseline n Baseline Change from baseline n Baseline Change from baseline
PVR (dyn·s·cm–5) 11 1312±763 -66±632 13 1130±664 -250±410 7 1047±564 -126±368
NT-proBNP (pg/mL) 12 1573±1775 -46±697 13 761±1172 -164±317a 7 1352±1350 -872±1147a
WHO FC (%) 12 II – 58% Improved 8% 15 II – 67% Improved 21% 8 II – 50% Improved 29%
   III – 42% Stabilized 83%   III – 33% Stabilized 79%   III – 50% Stabilized 71%
    Worsened 8%    Worsened 0%a    Worsened 0%a
Borg dyspnea score 12 4.3±2.7 -0.1±2.4 15 2.5±1.4 -0.3±1.3b 8 3.2±1.6 -0.8±0.8a
EQ-5D score 12 0.74±0.16 -0.05±0.22 15 0.78±0.15 0.03±0.18a 8 0.74±0.08 +0.09±0.14a
LPH score 12 40.4±20.0 -0.1±15.8 15 34.9±26.0 -8.0±15.9a 8 40.0±15.3 -13.7±13.2a
  1. Data are mean±SD unless otherwise indicated.
  2. a Data missing for one patient.
  3. b Data missing for two patients. EQ-5D, EuroQol Group 5-Dimension Self-report Questionnaire; Living with Pulmonary Hypertension questionnaire NT-proBNP, N-terminal prohormone of brain natriuretic peptide; PVR, pulmonary vascular resistance; WHO FC, World Health Organization functional class